Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by OysterBuctoucheon Nov 05, 2020 7:39pm
186 Views
Post# 31849019

RE:RE:RE:RE:Money money money

RE:RE:RE:RE:Money money moneyBioasis has a world class science. Often there is commentary and comparison to Denali Therapeuttics. To put the money money money issue in perspective Denal R & D expense in the last quarter was 53 million. Reported loss for the quarter was 58 million. 

We are still around because of the science and with continued progress we can limp through this to major success, But make no mistake we are advancing like a snail because we have little to no money. But that is okay. We are getting there.....This is not a criticism but rather statement of fact. I temper my expectations in relation to the cash on hand. Dont forget pre Chiesi we went many many months with no cash (hello Xoma). I dont know the details but feels pretty impressive DR could navigate a Chiesi deal when she was out of bullets and running out of time. 

Onward and upward for this little beast !
<< Previous
Bullboard Posts
Next >>